EUVIMEDEUVIMED entdecken
Open Access

Development of a Patient-Reported Outcome Measure for Hypereosinophilic Syndrome

Paneez Khoury, Sana Mahmood, Alexis Berry, Dominique Mata, Miriam Kimel, Julie McCormack, Calman Prussin, Amy Klion

The Journal of Allergy and Clinical Immunology: In Practice · 2025

DOI: 10.1016/j.jaip.2025.09.008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2025. Verfasst von Paneez Khoury und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Md; L…. Hauptthemen laut MEDLINE: Hypereosinophilic Syndrome, Patient Reported Outcome Measures, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS, National Institutes of Health National Institute of Allergy and Infectious Diseases, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Although a phase 3 double-blind, placebo-controlled registration trial of mepolizumab for hypereosinophilic syndromes (HES) used a patient-reported severity assessment, no patient reported outcome (PRO) measures have been formally developed for HES. Prior attempts to develop a PRO have been unsuccessful. OBJECTIVE: The purpose of this study was to develop an outcome measure using accepted approaches for qualitative methods, conceptual models, and analyses to detect symptom severity and patient experience of disease activity. METHODS: The study was performed using U.S. Food and Drug Administration guidance for development of symptom scales for outcome metrics using psychometric analysis and patient-administered questionnaires. Sixty-three heterogeneous patients with different HES subtypes enrolled on a natural history study of eosinophilia were invited to participate. All participants provided informed consent. At baseline, patients filled out an HES Symptom Inventory (HES-SI) and indicated up to 4 of their most bothersome symptoms (HES-MBS). Symptom fluctuation was recorded over the course of 3 months, and clinical metrics (treatment changes) were assessed during the same period. RESULTS: Across all timepoints, strong statistically significant correlations were observed for the HES-SI total score (r = 0.69-0.80; P < .0001) and HES-MBS score (r = 0.71-0.81; P < .0001) with the patients' perception of disease status (Patient Global Assessment). The HES-SI and HES-MBS showed sensitivity to change and demonstrated test-retest reliability. CONCLUSIONS: Analyses of the HES-SI and HES-MBS scores provided strong preliminary evidence supporting the reliability and validity of these measures for use in future HES clinical trials. The ability of these scales to accurately measure changes in HES symptoms with successful treatment requires further study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypereosinophilic SyndromePatient Reported Outcome MeasuresAntibodies, Monoclonal, HumanizedHumansMaleFemaleMiddle AgedAdultAgedSeverity of Illness IndexSurveys and QuestionnairesPsychometricsDouble-Blind MethodYoung Adult

Stichwörter der Autor:innen

EosinophiliaHypereosinophilic syndromesMost bothersome symptomPatient experiencePatient-reported outcomes

Substanzen

mepolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Md; Laboratory of Allergic Diseases, NIAID, NIH, Bethesda, Md. Electronic a…
  • Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Md.
  • Evidera, PPD clinical research business of Thermo Fisher Scientific, Wilmington, NC.
  • Areteia Therapeutics, Chapel Hill, NC.

Förderung

  • Intramural NIH HHS
  • National Institutes of Health National Institute of Allergy and Infectious Diseases
  • National Institutes of Health
  • U.S. Department of Health and Human Services

Zitieren

APA

Khoury, P., Mahmood, S., Berry, A., Mata, D., Kimel, M., McCormack, J., Prussin, C., & Klion, A. (2025). Development of a Patient-Reported Outcome Measure for Hypereosinophilic Syndrome. The Journal of Allergy and Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2025.09.008

Vancouver

Khoury P, Mahmood S, Berry A, Mata D, Kimel M, McCormack J, et al. Development of a Patient-Reported Outcome Measure for Hypereosinophilic Syndrome. The Journal of Allergy and Clinical Immunology: In Practice. 2025. doi:10.1016/j.jaip.2025.09.008

BibTeX
@article{Khoury2025,
  author = {Khoury, Paneez and Mahmood, Sana and Berry, Alexis and Mata, Dominique and Kimel, Miriam and McCormack, Julie and Prussin, Calman and Klion, Amy},
  title = {Development of a Patient-Reported Outcome Measure for Hypereosinophilic Syndrome},
  journal = {The Journal of Allergy and Clinical Immunology: In Practice},
  year = {2025},
  doi = {10.1016/j.jaip.2025.09.008}
}
Kostenlos starten →